US 6,455,043 B1Granted

Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody

AssigneeIDEC Pharmaceuticals Corporation

InventorAntonio J. Grillo-López

Life of this patent

Estimating the term…

Abstract

New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.

Claims15

Dependent claims

A method for reducing residual CD20+ tumor cells in bone marrow or stem cell tissue after myeloablative therapy in a subject in need of such treatment by administering an amount of a non-radiolabeled anti-CD20 antibody effective to reduce the number of residual CD20+ tumor cells in said bone marrow or stem cell tissue.

Dependencies are inferred from the claim text.

Facts

Application: 09/372,202Filed 11 Aug 1999 · us provisional application
Priority: 11 Aug 1998
Granted: 24 Sep 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification30 codes

C07K 16/2887
Against receptors, cell surface antigens or cell surface determinants: against CD20
A61K 31/475
Quinolines; Isoquinolines: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
A61K 31/573
Substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone: substituted in position 21, e.g. cortisone,…
A61K 31/675
Phosphorus compounds: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Family

Application60/096,180Us provisional application · filed 11 Aug 1998
US 6,455,043 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results